Why invest
Our vision is to make MOB-015, launched in Sweden and Norway under the brand name Terclara®, the leading nail fungus treatment globally, and to build a specialty pharmaceutical company with our own sales in the U.S. and sales through partners in other markets.
World-leading anti-fungal effect
- 76% of the patients became fungus-free in two phase 3 studies that included over 800 patients
- MOB-015 is a topical formulation of terbinafine. 1000 times lower concentration of terbinafine in the blood compared to oral treatment.
- Strong premium position from true competitive advantage: Targeting category leadership with USD 250-500m potential global product sales
Strong commercial partners in place
Europa, APAC, China
Scandinavia
Canada
Israel
Market leader in nail fungus
- Terclara® became the market leader in Sweden and Norway instantly after starting consumer marketing
- National marketing authorization approvals received in 14 countries, whereof 8 granted OTC status. The rollout is ongoing together with Karo Healthcare.
- Builds on previous successes with the first-generation product Kerasal Nail®/Nalox®, which was sold for 1.4 billion SEK
Significant events during the latest quarter
- Launch preparations and marketing activities for the first European countries, together with partner Karo Healthcare, are progressing according to plan with first deliveries around year-end.
- In September, marketing to dermatologists in Israel began through partner Padagis Israel Agencies Ltd. The launch follows regulatory clearance by the Israeli Ministry of Health (MOH) for the first commercial batch. As in the Nordics, the product is being launched under Moberg Pharma’s brand name Terclara®.
- The organization was strengthened ahead of upcoming launches, with two new members joining the management team: Helena Jansson, Chief Business Officer and Deputy CEO, and Vaidrius Navikas, Chief Medical Officer.
Share Price
Calendar
Latest Press Releases